etx-difuse hormones-ch5-fig7

Figure 7. The current means of targeting the biologic processes promoting cell growth in PNETs. Somatostatin analogs w bind to somatostatin receptors controlling both symptoms and cell growth. Sunitinib is a tyrosine kinase inhibitor which VEGFR and PDGFR. Everolimus is an mTOR inhibitor. The result is inhibition of tumor angiogenesis and or cancer cell proliferation. Legend: mTOR, mammalian target of Rapamycin; PDGFR, platelet-derived growth factor receptor; SSR, somatostatin receptors; VEGFR, vascular endothelial growth receptor. Reprinted from Faivre, S., et al. Novel anticancer agents in clinical trials for well-differentiated NETS Endocrinol Metab Clin North Am 2010,31(4)-811-26.